We don’t follow footsteps.
We create the path.

News & events

Hemophilia B Program Transitioned to Pfizer Spark Therapeutics completes transition of the SPK-9001 program in hemophilia B to Pfizer.  

Read More read more

Updated Hemophilia B Data Presented Spark Therapeutics presented data from its Phase 1/2 study of investigational SPK-9001 at the World Federation of Hemophilia 2018 Congress

Read More read more

Gene Therapy Approval FDA has approved our gene therapy product

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More